FDA clears Pluvicto plus ARPI for PSMA-positive mAPMN/S prostate cancer
AI Market Summary
The FDA's July 31 approval of LuPSMA-617 (Pluvicto) plus ARPI for PSMA-positive mAPMN/S prostate cancer expands an earlier-line indication, supported by improved rPFS (HR 0.72) in the Phase III PSMAddition trial. The news is sector-specific and primarily affects oncology therapeutics and imaging diagnostics demand, with limited immediate read-through to broad macro assets or crypto.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.00%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The U.S. FDA approved targeted radionuclide therapy LuPSMA-617 (Pluvicto) in combination with an androgen receptor pathway inhibitor (ARPI) on July 31 for PSMA-positive metastatic androgen pathway modulation–naive or–sensitive (mAPMN/S) prostate cancer. The decision was supported by the phase 3 PSMAddition trial, which showed the combination significantly improved radiographic progression-free survival versus ARPI alone. The reported hazard ratio for rPFS was 0.72.
